Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.

Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT.

J Dev Behav Pediatr. 2008 Aug;29(4):293-302. doi: 10.1097/DBP.0b013e31817dc447.

PMID:
18698192
2.

Open-label add-on treatment trial of minocycline in fragile X syndrome.

Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW.

BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.

3.

Open-label riluzole in fragile X syndrome.

Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ.

Brain Res. 2011 Mar 22;1380:264-70. doi: 10.1016/j.brainres.2010.10.108. Epub 2010 Nov 5.

PMID:
21059347
4.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B.

Sci Transl Med. 2011 Jan 5;3(64):64ra1. doi: 10.1126/scitranslmed.3001708.

5.

Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome.

Kim SH, Markham JA, Weiler IJ, Greenough WT.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4429-34. doi: 10.1073/pnas.0800257105. Epub 2008 Mar 10.

6.

Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.

Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST.

Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42. Epub 2007 Sep 19.

7.

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.

Çaku A, Pellerin D, Bouvier P, Riou E, Corbin F.

Am J Med Genet A. 2014 Nov;164A(11):2834-42. doi: 10.1002/ajmg.a.36750. Epub 2014 Sep 24.

PMID:
25258112
8.

A prospective open-label study of aripiprazole in fragile X syndrome.

Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ.

Psychopharmacology (Berl). 2011 Jul;216(1):85-90. doi: 10.1007/s00213-011-2194-7. Epub 2011 Feb 12.

PMID:
21318565
9.
10.

Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium.

Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, Calabrese JR.

J Am Acad Child Adolesc Psychiatry. 2004 Feb;43(2):215-20.

PMID:
14726729
11.

Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome.

Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT.

Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1253-7. doi: 10.1002/ajmg.b.30765.

PMID:
18452182
12.

Open-label memantine in fragile X syndrome.

Erickson CA, Mullett JE, McDougle CJ.

J Autism Dev Disord. 2009 Dec;39(12):1629-35. doi: 10.1007/s10803-009-0807-3. Epub 2009 Jul 16.

PMID:
19609663
13.

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ.

Sci Transl Med. 2012 Sep 19;4(152):152ra127.

14.

Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.

Wang X, Snape M, Klann E, Stone JG, Singh A, Petersen RB, Castellani RJ, Casadesus G, Smith MA, Zhu X.

J Neurochem. 2012 May;121(4):672-9. doi: 10.1111/j.1471-4159.2012.07722.x. Epub 2012 Mar 27.

15.

Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.

McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA.

Neuron. 2005 Mar 3;45(5):753-64.

16.

Arbaclofen in fragile X syndrome: results of phase 3 trials.

Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL.

J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017.

17.

Differential translation and fragile X syndrome.

Vanderklish PW, Edelman GM.

Genes Brain Behav. 2005 Aug;4(6):360-84. Review.

19.

Development of mavoglurant and its potential for the treatment of fragile X syndrome.

Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S.

Expert Opin Investig Drugs. 2014 Jan;23(1):125-34. doi: 10.1517/13543784.2014.857400. Epub 2013 Nov 20. Review.

PMID:
24251408
20.

Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome.

King MK, Jope RS.

Genes Brain Behav. 2013 Oct;12(7):723-31. doi: 10.1111/gbb.12071. Epub 2013 Aug 29.

Supplemental Content

Support Center